Researchers from the Translation Center for Regenerative Therapies TLC-RT at the Fraunhofer Institute for Silicate Research ISC, working in collaboration with B-COS GmbH, have developed a ...
Novo Nordisk will pay $300 million upfront, and up to $2.6 billion in total, for Hengrui's once-weekly GLP-1/GIP pill, which has not been tested in people. North Carolina Budget Sends Over $10.7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results